Axonics® to Present at Upcoming Investor Conferences
Raymond W. Cohen, Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch Healthcare Conferenceon Wednesday, May 15, at 10:15 am PDTat the Encore in Las Vegas.
Cohen is also scheduled to present at the
UBS Global Healthcare Conferenceon Wednesday, May 22, at 9:00 am EDTat the Grand Hyattin New York City.
To access the live webcast of the presentations at the aforementioned conferences, please visit the Events & Presentations page of the Investors section of the Company's website at ir.axonicsmodulation.com. A replay of the webcasts will be available shortly after the conclusion of the presentations and will be archived on the Company's website for 90 days.
Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics r-SNM® System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain CE mark for full-body MRI conditional labeling. Premarket Approval (PMA) for the r-SNM System is currently pending with the U.S. FDA. For more information, visit the Company’s website at www.axonicsmodulation.com.
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
Investor & Media Contact
Matt Clawson, +1-949-370-8500